Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Classifica tra le azioni #11774
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Prezzo delle azioni
$1.77
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$660.45M
Variazione (1 giorno)
7.26%
Variazione (1 anno)
-9.15%
Paese
AU
Scambia Clarity Pharmaceuticals Ltd (CU6)

Categoria

Storico del rendimento da dividendi per Clarity Pharmaceuticals Ltd (CU6)
Il rendimento da dividendi (TTM) di Clarity Pharmaceuticals Ltd (simbolo azionario: CU6) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Clarity Pharmaceuticals Ltd (CU6) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti